Size: px
Start display at page:

Download ""

Transcription

1 MEETING PROSPECTUS

2 CONTENT Introduction... 3 Workshop description... 4 Background...4 Meeting Objectives...4 Learning Objectives...4 Format...4 Unique Meeting Features...4 Target audience...5 Demographics...5 Geographical distribution last meeting...5 Program Committee... 6 Participants Feedback Personal benefits...7 Content...7 Lectures...8 Metrics Pre-workshop communications...10 Post-workshop communications...10 Most effective elements...11 Quotes...11 Summary

3 INTRODUCTION The Workshop on HCV Therapy Advances was initiated three years ago and has been designed to educate treating physicians and researchers on the latest developments in the field of hepatitis treatment and the promising new treatment possibilities of new direct antivirals that are becoming available. The meeting is intended as a platform for sharing data and discussing the clinical application of these new antivirals in an interactive setting. The conference presentations by international key opinion leaders are focused on the translation of the latest scientific data and availability of new drugs into daily clinical practice. Clinical case discussions are also an important part of the program, in order to stimulate interaction and allow discussions on local issues. This meeting prospectus is designed in order to provide information on the meeting set up, demographics and metrics and also on the evaluation scores from the 2013 workshop participants. We hope this information is of interest. Please contact us if specific information is missing and we will gladly provide you with additional documentation. We would surely welcome your suggestions for improvement of this workshop in order to best serve the Hepatitis treating community in Europe. On behalf of the Program Committee, STEFAN ZEUZEM, MD JW Goethe University Hospital Frankfurt, Germany FRED POORDAD, MD Texas Liver Institute / University of Texas Health Science Center, USA CHARLES BOUCHER, MD, PHD Erasmus Medical Center, Rotterdam, The Netherlands 3

4 WORKSHOP DESCRIPTION BACKGROUND The entrance of HCV direct acting antivirals into routine clinical practices provides a great opportunity for improved care, but at the same time, substantial challenges for the treating physician. The Workshop on HCV Therapy Advances has been developed to educate treating physicians and researchers, to discuss the latest developments in the field of hepatitis treatment and the promising new treatment possibilities of new direct antivirals that are becoming available. The meeting is intended as a platform for sharing data and discussing the clinical application of these new antivirals. The conference presentations and case discussions presented by international recognized experts in the field are focused on the translation of the latest scientific data and availability of new drugs into daily clinical practice. MEETING OBJECTIVES The objective of this meeting is to create an interactive setting, in which key opinion leaders present and discuss the latest scientific data on clinical management of hepatitis infected patients. LEARNING OBJECTIVES After participating in this activity, the participants will: Have an understanding of the basic concepts of HCV therapy Be updated on the latest developments in the field of HCV antiviral research Have an understanding of the challenges of HCV treatment in different patient populations Have an overview of the advantages and possibilities of new antivirals in HCV therapy Know how to apply direct acting antivirals in clinical practice FORMAT This 1,5 day independent, scientific and educational workshop consists of invited lectures, round-table discussions and clinical case presentations. In order to ascertain an interactive workshop setting, much time is allocated to discussions. UNIQUE MEETING FEATURES The workshop is a unique European platform for clinicians and other professionals working in the field of viral hepatitis, translating new data into new treatment strategies to further improve clinical care The workshop attracts different disciplines involved in the field of HCV therapy The workshop includes the latest data presented at EASL, APASL and AASLD. The workshop stimulates European collaborations and networks The workshop stimulates updates on guidelines and encourages treatment efficiency 4

5 TARGET AUDIENCE Hepatologists Infectious disease doctors Gastroenterologists Other healthcare professionals involved in daily care of hepatitis patients Post-graduate students DEMOGRAPHICS 2013 Clinicians 71% Researchers 0% Marketing person 6% Post -graduate students 0% Other 24% TOTAL number of registrants 100 Returning participants 33,3% New participants 66,7% GEOGRAPHICAL DISTRIBUTION LAST MEETING Australia 1 Russia 1 Austria 1 Saudi Arabia 1 Belgium 14 Spain 3 Finland 4 Sweden 1 France 13 The Netherlands 8 Germany 6 United Kingdom 3 Italy 21 USA 4 Mexico 1 5

6 PROGRAM COMMITTEE STEFAN ZEUZEM, MD JW Goethe University Hospital Frankfurt, Germany FRED POORDAD, MD Texas Liver Institute / University of Texas Health Science Center, USA CHARLES BOUCHER, MD, PHD Erasmus Medical Center, Rotterdam, The Netherlands 6

7 PARTICIPANTS FEEDBACK 2013 PERSONAL BENEFITS This meeting improved my: Agree Neutral Disagree Medical or practical knowledge 100% 0% 0% Care attitudes 71,4% 28,6% 0% Procedural or cognitive skills 66,7% 33,3% 0% Practice behaviour 83,3% 16,7% 0% Patient s clinical outcomes 66,7% 16,7% 16,7 I would recommend this meeting to my colleagues: 86% I plan to attend this meeting again next year: 86% CONTENT Agree Neutral Disagree The content of the meeting met my expectations 85,7% 14,3% 0% Sufficient time allocated for discussion during the meeting 85,7% 14,3% 0% The allocated time per presentation was sufficient 85,7% 14,3% 0% I perceived no commercial bias at the meeting: 100% 7

8 PARTICIPANTS FEEDBACK 2013 LECTURES We are very proud of the evaluation of the invited lectures. Unfortunately Dr. Perno was not able to attend the meeting. FRIDAY, 13 DECEMBER Session 1: DAA s in combination with pegylated interferon and ribavine Boceprevir and telaprevir: efficacy and side effects, what have we learned in 2013 Fred Poordad, MD University of San Antonio Health Science Center, USA Novel DAA s combined with PEG/RIBA Heiner Wedemeyer, MD Hannover Medical School, Germany Content 100% 0% 0% Presentation 100% 0% 0% Content 100% 0% 0% Presentation 100% 0% 0% Session 2: DAA s in clinical development: what are the key A findings Simeprevir overview: From IFN-Containing to IFN-Free Regimens Maria Beaumont, MD Janssen Infectious Diseases Diagnostics BVBA, Belgium Content 100% 0% 0% Presentation 92,9% 7.1% 0% Session 3: Challenging Patient Populations Managing and monitoring of HCCi in the future era of DAA Massimo Colombo, MD University of Milan, Italy The current challenges in treating cirrhotic patients Marc Bourlière, MD Hôpital Saint Joseph, Marseille, France Content 80% 20% 0% Presentation 80% 20% 0% Content 80% 20% 0% Presentation 100% 0% 0% 8

9 SATURDAY, 14 DECEMBER Session 4: Genotype 2&3 and drug resistance Treating HCV genotype 2 & 3 Christophe Sarrazin, MD J.W. Goethe Hospital, Germany Drug resistance findings observed in clinical practice: implications for patient management Carlo Federico Perno, MD, PhD University of Rome Tor Vegata, Italy Latest insights from NUC- containing regimens: what is the best partner molecule? Geoffrey Dusheiko, MD UCL Institute for Liver and Health, Royal Free Hospital, UK Content 85,7% 14,3% 0% Presentation 100% 0% 0% Content Presentation Content 85,7% 14,3% 0% Presentation 85,7% 14,3% 0% Session 5: Interferon Free regimes NUC sparing regimens: where do we stand Stefan Zeuzem, MD J.W. Goethe Hospital, Germany Update: Early investigational trials Peter Ferenci, MD Medical University of Vienna, Austria Content 83,3% 16,7% 0% Presentation 100% 0% 0% Content 50% 50% 0% Presentation 50% 50% 0% 9

10 METRICS 2013 PRE-WORKSHOP COMMUNICATIONS Frequency/ Number Publicity through electronic newsletter 5 x per year / 4121 persons Flyers at other meetings Publicity on conference websites Invitations from industry Endorsements by the following two societies: - Italian Society for Infectious and Tropical Diseases - Italian Association for the Study of the Liver 4 meetings 30 websites yes used their databases for comunications Participants were asked how they heard about this activity. Below are the results: Percentage VE Newsletter 7% Invitation industry 47% VE Website 7% Internet research 13% Flyer at other meetings 0% Other conference agenda 7% Worth of mouth 20 % POST-WORKSHOP COMMUNICATIONS Workshop materials sent to workshop participants + participants previous years. Reviews in Antiviral Therapy & Infectious Diseases Frequency/Number +/ persons 600 hard copy editions and online available on our workshop website ( infectiousdiseasesonline.com/) Publications of presentations by industry 1 10

11 MOST EFFECTIVE ELEMENTS QUOTES The most effective element of this activity was the exchange of clinically relevant managing strategies Interesting discussion of both sessions and oral presentations. Lectures were of high level. Presentations were very informative for us who are not directly involved in the treatment of patients but still provide the analysis for the clinicians. The presentations followed by discussion. Clinical cases presentations and the discussions on this were very interesting and helpful for clinical practice. It s a good way to drive the discussion. 11

12 SUMMARY The Workshop on HCV Therapy Advances Meeting is a unique platform for sharing the most recent data and discussing the clinical application of these new antivirals in an interactive setting. The overall opinion of the meeting was very positive, as can be deducted from the above scores. As the vast majority of the audience consisted of clinicians, we can conclude that the aim of the meeting has been reached. Furthermore, delegates were satisfied with the scientific content of the workshop as well as with the format of the program. The format of this workshop has stimulated a high-level discussion among key opinion leaders and the expert faculty scored an average of 8.6 points for their lectures (on a scale of 1-10, 10 being excellent). Participants were also very pleased with the communication, logistics and content of the meeting. 86 % of the participants would recommend this workshop to their colleagues and more than 86% plans to attend this workshop again next year. Within one week after the meeting, the presentations were made available on the Virology Education website. The success and educational effect of this workshop have underlined the need for continuation. The Program Committee is pleased with the results of the 3 rd Workshop on HCV Therapy Advances and therefore looks forward to organizing the 4 th and 5 th edition of this workshop and welcoming old and new participants. The 4 th edition of the workshop will be held on December 2014 in Paris, France and the 5 th edition will be held in Barcelona, Spain on December

10 5 TH TH WORKSHOP INTERNATIONAL WORKSHOP ON CO-INFECTION NEW ANTIVIRALS IN CLINICAL PRACTICE HIV & HEPATITIS AMSTERDAM, PARIS, FRANCE THE NETHERLANDS 12-13 JUNE 2014 4-5 DECEMBER 2015 MEETING PROSPECTUS

More information

12 TH INTERNATIONAL WORKSHOP ON CO-INFECTION HIV & HEPATITIS BERLIN, GERMANY JUNE 2016 MEETING PROSPECTUS www.virology-education.com CONTENT Introduction... 3 Workshop description... 4 Background... 4

More information

11 TH INTERNATIONAL WORKSHOP ON CO-INFECTION HIV & HEPATITIS LONDON, UNITED KINGDOM 11-12 JUNE 2015 MEETING PROSPECTUS www.virology-education.com CONTENT Introduction... 3 Workshop description... 4 Background...

More information

under the aegis of cover picture: Chiostro d Onore University of Milan

under the aegis of cover picture: Chiostro d Onore University of Milan under the aegis of cover picture: Chiostro d Onore University of Milan Milan. 2,3 July 2012 Palazzo Visconti MEETING AIM In the last year the therapeutic scenario of chronic hepatitis C has been subverted

More information

HIV FORA: INTEGRATING SCIENCE AND CLINICAL PRACTICE EUROPEAN HIV FORUM: INTEGRASE INHIBITORS MILAN, ITALY 24 OCTOBER 2017 MEETING PROSPECTUS 2017 www.virology-education.com INTRODUCTION & SIGNIFICANCE

More information

The need for surveillance: How to implement it? Stephanie Popping, MD. Erasmus Medical Center Rotterdam

The need for surveillance: How to implement it? Stephanie Popping, MD. Erasmus Medical Center Rotterdam The need for surveillance: How to implement it? Stephanie Popping, MD. S.Popping@erasmusmc.nl Erasmus Medical Center Rotterdam Era of direct-acting antivirals HCV treatment changed incredibly DAAs are

More information

MEETING PROSPECTUS. HIV CLINICAL FORUM INTEGRASE INHIBITORS DURBAN, SOUTH AFRICA 16 July 2016

MEETING PROSPECTUS. HIV CLINICAL FORUM INTEGRASE INHIBITORS DURBAN, SOUTH AFRICA 16 July 2016 MEETING PROSPECTUS HIV CLINICAL FORUM INTEGRASE INHIBITORS DURBAN, SOUTH AFRICA 16 July 2016 VIROLOGY EDUCATION BILTSTRAAT 106 3572 BJ UTRECHT THE NETHERLANDS +31 30 230 7140 INFO@VIROLOGY-EDUCATION.COM

More information

HIV FORA: INTEGRATING SCIENCE AND CLINICAL PRACTICE EUROPEAN HIV FORUM: INTEGRASE INHIBITORS MILAN, ITALY 24 OCTOBER 2017 MEETING PROSPECTUS 2017 www.virology-education.com INTRODUCTION & SIGNIFICANCE

More information

1 ST EUROPEAN. NASH Workshop BARCELONA, SPAIN 8-9 MARCH 2019 REQUEST FOR SUPPORT.

1 ST EUROPEAN. NASH Workshop BARCELONA, SPAIN 8-9 MARCH 2019 REQUEST FOR SUPPORT. 1 ST EUROPEAN NASH Workshop BARCELONA, SPAIN 8-9 MARCH 2019 REQUEST FOR SUPPORT NEEDS ASSESSMENT NEEDS ASSESSMENT Non-alcoholic fatty liver disease (NAFLD) is an emerging liver disease affecting 25 % of

More information

MEETING PROSPECTUS 3 RD EUROPEAN WORKSHOP ON WORKSHOP ON HEALTHY LIVING WITH HIV.

MEETING PROSPECTUS 3 RD EUROPEAN WORKSHOP ON WORKSHOP ON HEALTHY LIVING WITH HIV. 3 RD EUROPEAN WORKSHOP ON WORKSHOP ON HEALTHY LIVING WITH HIV BARCELONA, SPAIN, TBC SEPTEMBER 2018 TBC MEETING PROSPECTUS www.hivhealthyliving.com www.expertmedicalevents.com ADVANCING HEALTH GLOBALLY

More information

INTERNATIONAL MASTERCLASS ON LIVER DISEASE IN HIV VILNIUS, LITHUANIA 18 SEPTEMBER 2019 (TBC) REQUEST FOR SUPPORT.

INTERNATIONAL MASTERCLASS ON LIVER DISEASE IN HIV VILNIUS, LITHUANIA 18 SEPTEMBER 2019 (TBC) REQUEST FOR SUPPORT. INTERNATIONAL MASTERCLASS ON LIVER DISEASE IN HIV VILNIUS, LITHUANIA 18 SEPTEMBER 2019 (TBC) REQUEST FOR SUPPORT INTRODUCTION Liver disease in the setting of HIV is increasingly presenting a major concern

More information

EVALUATION REPORT

EVALUATION REPORT International Workshop on NASH Biomarkers 2017 5-6 May 2017 Washington, D.C., EVALUATION REPORT www.expertmedicalevents.com/nashbiomarkers EXECUTIVE SUMMARY INTRODUCTION The 2 nd International Workshop

More information

13TH INTERNATIONAL WORKSHOP ON CO-INFECTION HIV & HEPATITIS LISBON, PORTUGAL 24-26 MAY 2017 SPONSORSHIP REQUEST 2017 www.expertmedicalevents.com INTRODUCTION & SIGNIFICANCE BACKGROUND Support our efforts

More information

SPONSORSHIP REQUEST 2017 INTEREST HIV TREATMENT, PATHOGENESIS AND PREVENTION RESEARCH IN RESOURCE-LIMITED SETTINGS.

SPONSORSHIP REQUEST 2017 INTEREST HIV TREATMENT, PATHOGENESIS AND PREVENTION RESEARCH IN RESOURCE-LIMITED SETTINGS. 11 TH INTERNATIONAL WORKSHOP ON HIV TREATMENT, PATHOGENESIS AND PREVENTION RESEARCH IN RESOURCE-LIMITED SETTINGS INTEREST LILONGWE, MALAWI MAY 16-19 2017 SPONSORSHIP REQUEST 2017 www.virology-education.com

More information

Access to treatment and disease burden

Access to treatment and disease burden Access to treatment and disease burden Robert Flisiak Department of Infectious Diseases and Hepatology Medical University in Białystok, Poland Moulin de Vernègues, 27-29 August 2015 Disclosures Advisor

More information

INTERNATIONAL CONFERENCE ON MYELOID CELLS AND HIV ITALY 1-3 SEPTEMBER 2018 MEETING PROSPECTUS.

INTERNATIONAL CONFERENCE ON MYELOID CELLS AND HIV ITALY 1-3 SEPTEMBER 2018 MEETING PROSPECTUS. INTERNATIONAL CONFERENCE ON MYELOID CELLS AND HIV ITALY 1-3 SEPTEMBER 2018 MEETING PROSPECTUS ADVANCING HEALTH GLOBALLY THROUGH INNOVATIVE PROGRAMS DESIGNED FOR THE HEALTHCARE PROFESSIONAL 2 TABLE OF CONTENTS

More information

Treating HCV Genotype 2 & 3

Treating HCV Genotype 2 & 3 Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy

More information

INTERNATIONAL WORKSHOP ON HIV & TRANSGENDER PEOPLE MEXICO CITY, MEXICO JULY 2019 MEETING PROSPECTUS.

INTERNATIONAL WORKSHOP ON HIV & TRANSGENDER PEOPLE MEXICO CITY, MEXICO JULY 2019 MEETING PROSPECTUS. INTERNATIONAL WORKSHOP ON HIV & TRANSGENDER PEOPLE MEXICO CITY, MEXICO JULY 2019 MEETING PROSPECTUS INTRODUCTION Dear Colleagues, It is our pleasure to announce the organization of the first Workshop focusing

More information

Comparison of two HCV-RNA assays assessing early response to simeprevir+pegifn/rbv to select patients suitable to shorten therapy to 12 weeks

Comparison of two HCV-RNA assays assessing early response to simeprevir+pegifn/rbv to select patients suitable to shorten therapy to 12 weeks Comparison of two HCV-RNA assays assessing early response to simeprevir+pegifn/rbv to select patients suitable to shorten therapy to 12 weeks C Sarrazin, 1 M Buti, 2 C Moreno, 3 M Gschwantler, 4 GR Foster,

More information

MEETING PROSPECTUS. International Workshop on NASH Biomarkers

MEETING PROSPECTUS. International Workshop on NASH Biomarkers International Workshop on NASH Biomarkers 2018 18-19 May 2018 Washington, D.C., USA MEETING PROSPECTUS www.expertmedicaleducation.com www.expertmedicalevents.com ADVANCING HEALTH GLOBALLY THROUGH INNOVATIVE

More information

REQUEST FOR SUPPORT 5 TH CENTRAL AND EASTERN EUROPEAN MEETING ON VIRAL HEPATITIS AND HIV BUDAPEST, HUNGARY OCTOBER 2019 (TBC)

REQUEST FOR SUPPORT 5 TH CENTRAL AND EASTERN EUROPEAN MEETING ON VIRAL HEPATITIS AND HIV BUDAPEST, HUNGARY OCTOBER 2019 (TBC) 5 TH CENTRAL AND EASTERN EUROPEAN MEETING ON VIRAL HEPATITIS AND HIV BUDAPEST, HUNGARY 10-11 OCTOBER 2019 (TBC) REQUEST FOR SUPPORT OVERVIEW INTRODUCTION The main objective of the Central and European

More information

BE RECOGNIZED IN THE DEMOLITION INDUSTRY BECOME A MEMBER OF EDA

BE RECOGNIZED IN THE DEMOLITION INDUSTRY BECOME A MEMBER OF EDA BE RECOGNIZED IN THE DEMOLITION INDUSTRY BECOME A MEMBER OF EDA What is EDA? 58% of companies noticed GROWTH in their business related to demolition in the past 3 years EDA Industry Report 2016 The European

More information

Survey Responses to the EUROPEAN COCOA FORUM 2016

Survey Responses to the EUROPEAN COCOA FORUM 2016 Survey Responses to the EUROPEAN COCOA FORUM The survey was sent to all delegates, speakers and moderators who took part in the European Cocoa Forum in Dubrovnik, and aimed at gathering feedback on the

More information

IVHEM 2019 REQUEST FOR SUPPORT INTERNATIONAL VIRAL HEPATITIS ELIMINATION MEETING.

IVHEM 2019 REQUEST FOR SUPPORT INTERNATIONAL VIRAL HEPATITIS ELIMINATION MEETING. INTERNATIONAL VIRAL HEPATITIS ELIMINATION MEETING 2019 AMSTERDAM, THE NETHERLANDS 22-23 NOVEMBER 2019 REQUEST FOR SUPPORT OVERVIEW INTRODUCTION TO The 5th edition of was organized on 6-7 December 2018

More information

Information Magazine for people with Hepatitis C and HIV. Hepatitis C - Treatment in people with haemophilia, the results to date

Information Magazine for people with Hepatitis C and HIV. Hepatitis C - Treatment in people with haemophilia, the results to date Positive News Information Magazine for people with Hepatitis C and HIV Hepatitis C - Treatment in people with haemophilia, the results to date From July 2012 to October 2013, a total of fifteen persons

More information

9TH INTERNATIONAL WORKSHOP ON HIV&AGING EAST COAST, USA OCTOBER 2018 MEETING PROSPECTUS.

9TH INTERNATIONAL WORKSHOP ON HIV&AGING EAST COAST, USA OCTOBER 2018 MEETING PROSPECTUS. 9TH INTERNATIONAL WORKSHOP ON HIV&AGING EAST COAST, OCTOBER 2018 MEETING PROSPECTUS www.virology-education.com www.expertmedicalevents.com ADVANCING HEALTH GLOBALLY THROUGH INNOVATIVE PROGRAMS DESIGNED

More information

Arevir meeting Lize Cuypers

Arevir meeting Lize Cuypers Arevir meeting 2017 Reconstructing the HCV migration history to support public health efforts Lize Cuypers KU Leuven University of Leuven, Department of Microbiology and Immunology, Rega Institute for

More information

The HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany

The HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany : Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained

More information

New Therapeutic Strategies: Polymerase Inhibitors

New Therapeutic Strategies: Polymerase Inhibitors New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2

More information

MEETING PROSPECTUS CHALLENGES & SOLUTIONS INTERNATIONAL WORKSHOP ON HIV ADOLESCENCE CAPE TOWN, SOUTH AFRICA OCTOBER 2018

MEETING PROSPECTUS CHALLENGES & SOLUTIONS INTERNATIONAL WORKSHOP ON HIV ADOLESCENCE CAPE TOWN, SOUTH AFRICA OCTOBER 2018 INTERNATIONAL WORKSHOP ON HIV ADOLESCENCE CHALLENGES & SOLUTIONS CAPE TOWN, SOUTH AFRICA 10-12 OCTOBER 2018 MEETING PROSPECTUS WELCOME Dear Colleague, We are proud to announce the 2nd International Workshop

More information

Curing Hepatitis C: Current And Future Options For Treatment By Gregory T. Everson, Gene Schiff READ ONLINE

Curing Hepatitis C: Current And Future Options For Treatment By Gregory T. Everson, Gene Schiff READ ONLINE Curing Hepatitis C: Current And Future Options For Treatment By Gregory T. Everson, Gene Schiff READ ONLINE AASLD president will discuss current hepatitis B treatment options, to hepatitis C research,

More information

The Role of Liver Societies in the Global Viral Hepatitis Response

The Role of Liver Societies in the Global Viral Hepatitis Response The Role of Liver Societies in the Global Viral Hepatitis Response Anna S. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research

More information

Global Patient Survey. Country-Specific Report Belgium

Global Patient Survey. Country-Specific Report Belgium Global Patient Survey Country-Specific Report Belgium HCV Quest Country-Specific Report ABOUT HCV QUEST The biggest barrier I have faced in the fight against viral hepatitis is... no recognition, lack

More information

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center

More information

Wilhelminenspital, Vienna, Austria; 5 Queen Mary Hospital, University of London, Barts Health, London, UK; 6

Wilhelminenspital, Vienna, Austria; 5 Queen Mary Hospital, University of London, Barts Health, London, UK; 6 Shortening overall treatment to 12 weeks of simeprevir plus PR in treatment-naïve chronic hepatitis C genotype 1 patients: assessment of baseline and Week 2 on-treatment predictors of SVR T Asselah, 1

More information

Zimbra jan.klimas@ucd.ie The ISAM Newsletter has arrived From : ISAM Newsletter Sender : ISAM Newsletter Subject : The ISAM Newsletter

More information

Transformation of Chronic Hepatitis C Treatment

Transformation of Chronic Hepatitis C Treatment Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence

More information

Angelos Hatzakis. 10th Paris Hepatology Conference

Angelos Hatzakis. 10th Paris Hepatology Conference Angelos Hatzakis Professor of Epidemiology and Preventive Medicine Faculty of Medicine National and Kapodistrian University of Athens Co-Chair, Hepatitis B and C Public Policy Association 10th Paris Hepatology

More information

The Role of Liver Societies in the Global Viral Hepatitis Response

The Role of Liver Societies in the Global Viral Hepatitis Response The Role of Liver Societies in the Global Viral Hepatitis Response Anna S. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research

More information

What is the extent of gender bias in bioinformatics?

What is the extent of gender bias in bioinformatics? What is the extent of gender bias in bioinformatics? Keith R. Bradnam krbradnam@ucdavis.edu, @kbradnam Genome Center, University of California, Davis Introduction As a male bioinformatician, I was curious

More information

Baseline and acquired viral resistance to DAAs: how to test and manage

Baseline and acquired viral resistance to DAAs: how to test and manage Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline

More information

Summary Report EU Health Award 2017

Summary Report EU Health Award 2017 EPSA Vaccination Awareness Public Health Campaign 2016 Summary Report EU Health Award 2017 1. Introduction & Case Situation Background With WHO European Vaccine Action Plan 2015-2020 being developed and

More information

20 th MCCR WORKSHOP METHODS IN CLINICAL CANCER RESEARCH. Zeist, Netherlands Society Grant Prospectus 2018 JUNE. ecco-org.

20 th MCCR WORKSHOP METHODS IN CLINICAL CANCER RESEARCH. Zeist, Netherlands Society Grant Prospectus 2018 JUNE. ecco-org. 20 th MCCR WORKSHOP METHODS IN CLINICAL CANCER RESEARCH Zeist, Netherlands Society Grant Prospectus 2018 16-22 JUNE 2018 ecco-org.eu/workshop TABLE OF CONTENT 1. INTRODUCTION 3 2. EDUCATIONAL FORMAT 5

More information

47 th Annual Meeting AISF

47 th Annual Meeting AISF 47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,

More information

PHOTO. VHPB/ELPA MEETING Prevention and Control of Viral Hepatitis The role and impact of patients and advocacy groups in and outside Europe

PHOTO. VHPB/ELPA MEETING Prevention and Control of Viral Hepatitis The role and impact of patients and advocacy groups in and outside Europe www.eurordis.org VHPB/ELPA MEETING Prevention and Control of Viral Hepatitis The role and impact of patients and advocacy groups in and outside Europe Lucca ( Italy ) March 13-14, 2008 PHOTO www.eurordis.org

More information

Oral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside

Oral combination therapy: future hepatitis C virus treatment? Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following

More information

The following page contains the final YODA Project review approving this proposal.

The following page contains the final YODA Project review approving this proposal. The YODA Project Research Proposal Review The following page contains the final YODA Project review approving this proposal. The Yale University Open Data Access (YODA) Project Yale University Center for

More information

EPAG UPDATE. Lenja Wiehe. European Patient Advocacy Groups Manager, EURORDIS

EPAG UPDATE. Lenja Wiehe. European Patient Advocacy Groups Manager, EURORDIS EPAG UPDATE Lenja Wiehe European Patient Advocacy Groups Manager, EURORDIS Patient Centre & Empowerment European Reference Networks (ERNs) created on founding principles of patient-centred care, patient

More information

Introduction. About the Lupus Academy

Introduction. About the Lupus Academy Content Introduction Past Activities Barcelona 2012 Buenos Aires 2013 Further Development of the Lupus Academy Berlin 2014 Philippines (APLAR) 2014 Educational support programme Budgets 2 Introduction

More information

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients 5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,

More information

TREAT-NMD Neuromuscular Network

TREAT-NMD Neuromuscular Network TREAT-NMD Neuromuscular Network 16 th November 2007 Newsletter No. 21 Welcome to the latest newsletter from the TREAT-NMD network. This edition features a meeting report from last week s patient registry

More information

SPONSORSHIP OPPORTUNITIES

SPONSORSHIP OPPORTUNITIES CONFERENCES SPONSORSHIP OPPORTUNITIES 2 nd International Conference on Tropical and Infectious Diseases November 21-22, 2019 Bali, Indonesia our DELEGATE is your CLIENT Our Programme 5+ Keynote Sessions

More information

29th Viral Hepatitis Prevention Board Meeting

29th Viral Hepatitis Prevention Board Meeting 29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C

More information

SPONSORSHIP OPPORTUNITIES

SPONSORSHIP OPPORTUNITIES CONFERENCES SPONSORSHIP OPPORTUNITIES 5 th World Congress on Epigenetics and Chromosome November 15-16, 2018 Istanbul, Turkey our DELEGATE is your CLIENT Our Programme 5+ Keynote Sessions Our programme

More information

Table Of Content. The European Influenza Surveillance Scheme... 2 Summary... 3 Coordinator, Leader contact and partners Outputs...

Table Of Content. The European Influenza Surveillance Scheme... 2 Summary... 3 Coordinator, Leader contact and partners Outputs... Table Of Content The European Influenza Surveillance Scheme... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Institut Pasteur... 6 Health Division... 6 Nphs Communicable Disease Surveillance

More information

8 th Congress of ECCO

8 th Congress of ECCO European Crohn s and Colitis Organisation Vienna Austria 8 th Congress of ECCO Austria Center Vienna February 14-16, 2013 The major educational event in the field of Inflammatory Bowel Diseases in Europe

More information

The Smokefree Class Competition What is it about?

The Smokefree Class Competition What is it about? The Smokefree Class Competition What is it about? a universal smoking prevention programme for pupils aged 11-14 years. The main aims are to delay or prevent the onset of smoking to motivate adolescents

More information

NATIONAL REGISTRIES OF RARE DISEASES IN EUROPE: AN OVERVIEW BY THE EPIRARE PROJECT.

NATIONAL REGISTRIES OF RARE DISEASES IN EUROPE: AN OVERVIEW BY THE EPIRARE PROJECT. D. Taruscio and L. Vittozzi National Centre for Rare Diseases National Institute of Health Rome, Italy NATIONAL REGISTRIES OF RARE DISEASES IN EUROPE: AN OVERVIEW BY THE EPIRARE PROJECT. ICORD 2014, Ede

More information

Current Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany

Current Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,

More information

Optimal Treatment with Boceprevir. Michael Manns

Optimal Treatment with Boceprevir. Michael Manns Optimal Treatment with Boceprevir Michael Manns 6th Paris Hepatitis Conference, 14th January 2013 Acknowledgements Benjamin Maasoumy Optimal Patient Selection Defining the Ideal Candidate Treatment Urgency

More information

Global Patient Survey. Country-Specific Report China

Global Patient Survey. Country-Specific Report China Global Patient Survey Country-Specific Report China HCV Quest Country-Specific Report ABOUT HCV QUEST Because of the side effects of IFN, I cannot get close to my children 1. Medical insurance/social

More information

Management of the Diabetic Foot

Management of the Diabetic Foot Pisa International Diabetic Foot Course 2019 Sponsor Information Management of the Diabetic Foot Theory & Practice 4-day course 2-5 October 2019 Pisa, Italy Theory Practice Network www.diabeticfootcourses.org

More information

World Connections Committee (WCC) Report

World Connections Committee (WCC) Report World Connections Committee (WCC) Report 06 Co-Dependents Anonymous Service Conference Countries Where CoDA Exists This report reflects the World Connections Committee (WCC) support of the growth and development

More information

WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017

WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017 WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017 Mary L. Yost 404-520-6652 , LLC 23 Ridge Rd. Beaufort, SC 20097 Copyright Pending 2017 All rights reserved,

More information

International Symposium on Quality Assurance for Analytical Methods in Isotope Hydrology

International Symposium on Quality Assurance for Analytical Methods in Isotope Hydrology IAEA-CN-119 International Symposium on Quality Assurance for Analytical Methods in Isotope Hydrology 25 27 August 2004 Vienna, Austria Announcement and Call for Papers 1. INTRODUCTION Scarcity of fresh

More information

Support & Exhibit Prospectus th ANNUAL CONFERENCE International Association for Dance Medicine & Science

Support & Exhibit Prospectus th ANNUAL CONFERENCE International Association for Dance Medicine & Science 27 th ANNUAL CONFERENCE International Association for Dance Medicine & Science Support & Exhibit Prospectus 2017 October 12-15, 2017 Houston, Texas, USA IADMS s W 27 th Annual and Exhibitor Benefit ELCOME

More information

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, 2014 ClinicalTrials.gov ID: NCT00372385 Study Identification Unique Protocol ID: VX05-950-104EU Brief Title:

More information

TRANSFORMING HCV MANAGEMENT

TRANSFORMING HCV MANAGEMENT TRANSFORMING HCV MANAGEMENT Summary of Presentations from the Gilead Sciences (Europe) Symposium, held at the 49 th Annual EASL ILC, London, UK, on 9 th April 2014 Chairperson Graham Foster, 1 Patrick

More information

Hepatitis C Resistance Associated Variants (RAVs)

Hepatitis C Resistance Associated Variants (RAVs) Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure

More information

Liver disease in 2017: challenges and opportunities

Liver disease in 2017: challenges and opportunities Liver disease in 2017: challenges and opportunities Dr Matthew Cowan Consultant Gastroenterologist and Hepatologist Surrey and Sussex Healthcare NHS Trust Faculty of Physician Associates 2 nd National

More information

SPONSORSHIP OPPORTUNITIES

SPONSORSHIP OPPORTUNITIES CONFERENCES SPONSORSHIP OPPORTUNITIES International Conference on Vaccines and Immune Response June 16-17, 2019 Dubai, UAE our DELEGATE is your CLIENT Our Programme 5+ Keynote Sessions Our programme aims

More information

Hepatitis C Update: What s New in 2017

Hepatitis C Update: What s New in 2017 Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu

More information

SPONSORSHIP OPPORTUNITIES

SPONSORSHIP OPPORTUNITIES CONFERENCES SPONSORSHIP OPPORTUNITIES International Conference on WOMEN S HEALTH, REPRODUCTION AND FERTILITY April 08-09, 2019 Abu Dhabi, UAE our DELEGATE is your CLIENT Our Programme 5+ Keynote Sessions

More information

squamous cell carcinoma of the head and neck (SCCHN)

squamous cell carcinoma of the head and neck (SCCHN) EGFR Advisors Network (EAN) meeting for squamous cell carcinoma of the head and neck (SCCHN) Through the patients eyes March 27 28, 2015 InterContinental Hotel Berlin, Germany Chairs to include: Athanassios

More information

National Women s Health Week Celebration

National Women s Health Week Celebration National Women s Week Celebration Tuesday, May 10, 2016 Lectures Workshops Exhibits Research Posters We invite your company or service to participate! Prentice Women s Hospital 3rd Floor 11:00 a.m. 2:00

More information

SPONSORSHIP CANADIAN GERIATRICS SOCIETY. 38th Annual Scientific Meeting April 19-21, 2018 Hotel Bonaventure, Montreal, QC CONTACT

SPONSORSHIP CANADIAN GERIATRICS SOCIETY. 38th Annual Scientific Meeting April 19-21, 2018 Hotel Bonaventure, Montreal, QC CONTACT CANADIAN GERIATRICS SOCIETY 38th Annual Scientific Meeting April 19-21, 2018 Hotel Bonaventure, Montreal, QC SPONSORSHIP 2018 PACKAGE CONTACT Andrea Smith, Conference Manager events@secretariatcentral.com

More information

The Academy for Clinical Debates & Controversies in Medicine C-HEP BARCELONA SPAIN MAY 19-22, 2011 ANNOUNCEMENT

The Academy for Clinical Debates & Controversies in Medicine C-HEP BARCELONA SPAIN MAY 19-22, 2011 ANNOUNCEMENT The Academy for Clinical Debates & Controversies in Medicine C-HEP 1 st World Congress on CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS Second ANNOUNCEMENT Last update: March 9, 2011 www.comtecmed.com/chep

More information

Support & Exhibit Prospectus th ANNUAL CONFERENCE International Association for Dance Medicine & Science

Support & Exhibit Prospectus th ANNUAL CONFERENCE International Association for Dance Medicine & Science IADMS s 28 th and Exhibitor Benefit 28 th ANNUAL CONFERENCE International Association for Dance Medicine & Science Support & Exhibit Prospectus 2018 October 25-28, 2018 Helsinki, Finland IADMS s W 28 th

More information

President s Message November 16, 2011

President s Message November 16, 2011 President s Message November 16, 2011 Dear House of Delegate s (HOD) Members: I am sending this additional report as there was insufficient space in Contact International (CI). The Executive Council (EC)

More information

Vosevi (sofosbuvir/velpatasvir/voxilaprevir)

Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Policy Number: 5.01.646 Last Review: 10/2017 Origination: 10/2017 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide

More information

Industry Partners. Information and Benefits

Industry Partners. Information and Benefits Industry Partners Information and Benefits 1968 to today Founded in 1968, the EACR is Europe s professional membership association for those working and studying in cancer research, with over 10,000 members

More information

PegIntron (Hepatitis C Virus) Forecast and Market Analysis to GDHC1143DFR / Published May 2013

PegIntron (Hepatitis C Virus) Forecast and Market Analysis to GDHC1143DFR / Published May 2013 PegIntron (Hepatitis C Virus) Forecast and Market Analysis to 2022 GDHC1143DFR / Published May 2013 Executive Summary PegIntron (peginterferon alfa-2b) Key Metrics in the Major Pharmaceutical Markets 2012

More information

HPV & CERVICAL CANCER POLICY & LEGISLATIVE TOOLKIT, 3 RD EDITION

HPV & CERVICAL CANCER POLICY & LEGISLATIVE TOOLKIT, 3 RD EDITION How-To Guide for Hosting Town Hall Meetings Town hall meetings can be an effective approach to educating a community about a particular issue, such as HPV and cervical cancer, while also engaging constituents

More information

rare diseases research through National Plans and Strategies

rare diseases research through National Plans and Strategies Recommendations to support rare diseases research through National Plans and Strategies Dr Domenica Taruscio EUROPLAN Coordinator Director of the Italian Centre for Rare Diseases, Italian National Institute

More information

ESMO FELLOWSHIP PROGRAMME & LEADERS GENERATION PROGRAMME

ESMO FELLOWSHIP PROGRAMME & LEADERS GENERATION PROGRAMME ESMO FELLOWSHIP PROGRAMME & LEADERS GENERATION PROGRAMME Christoph Zielinski Chair of the ESMO Fellowship & Award Committee esmo.org ESMO FELLOWSHIP PROGRAMME Exclusive to ESMO members under 40 years old

More information

Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use

Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use DOI 10.1007/s10620-011-1604-3 ORIGINAL ARTICLE Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use Paul J. Gaglio Noah Moss Camille McGaw John Reinus Received: 15 December 2010

More information

How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy

How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum

More information

The Disease Burden of Hepatitis C in Belgium : development of a realistic disease control strategy

The Disease Burden of Hepatitis C in Belgium : development of a realistic disease control strategy 280 POSITION PAPER : BELGIAN WORKING GROUP FOR HEPATITIS C The Disease Burden of Hepatitis C in Belgium : development of a realistic disease control strategy P. Stärkel 1, D. Vandijck 2,3, W. Laleman 4,

More information

European Patients Academy on Therapeutic Innovation

European Patients Academy on Therapeutic Innovation European Patients Academy on Therapeutic Innovation http://www.patientsacademy.eu info@patientsacademy.eu The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under

More information

Practical experience in implementing surveillance of antiviral resistance in several European countries in accordance with personal data regulation

Practical experience in implementing surveillance of antiviral resistance in several European countries in accordance with personal data regulation Practical experience in implementing surveillance of antiviral resistance in several European countries in accordance with personal data regulation Katja Deterding Medizinische Hochschule Hannover Antiviral

More information

Table Of Content. Page 1/8

Table Of Content. Page 1/8 Table Of Content 22nd Conference: Changing perceptions, practice and policy... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7 D04-00 - Programme and book of abstracts (EN)...

More information

4 th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 1. IAS 2007 Evaluation: Delegate Survey

4 th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 1. IAS 2007 Evaluation: Delegate Survey 4 th IAS Conference on HIV Pathogenesis, Treatment and Prevention Appendices 1. IAS 2007 Evaluation: Delegate Survey 2. Report of the longer-term impact of the 3 rd IAS Conference on HIV Pathogenesis,

More information

Case Study: Physician and Patient-Facing Medical Education APPs. Sandeep Pulim, MD Chief Medical Information Officer

Case Study: Physician and Patient-Facing Medical Education APPs. Sandeep Pulim, MD Chief Medical Information Officer Case Study: Physician and Patient-Facing Medical Education APPs Sandeep Pulim, MD Chief Medical Information Officer Quality IME Collaborating for Patient Care Commercial Supporter Medical Education Provider

More information

SPONSORSHIP OPPORTUNITIES

SPONSORSHIP OPPORTUNITIES CONFERENCES SPONSORSHIP OPPORTUNITIES World congress on Polycystic ovarian Syndrome and Fertility October 18-19, 2018 Abu Dhabi, UAE our DELEGATE is your CLIENT Our Programme 5+ Keynote Sessions PCOS2018

More information

IFN-free therapy in naïve HCV GT1 patients

IFN-free therapy in naïve HCV GT1 patients IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,

More information

FRIDAY, MARCH 9 SUNDAY, MARCH

FRIDAY, MARCH 9 SUNDAY, MARCH 33RD A N N U A L New Treatments in Chronic Liver Disease FRIDAY, MARCH 9 SUNDAY, MARCH 11, 2018 Pre-Conference: Friday, March 9, 2018 Main Conference: Saturday, March 10-11, 2018 Estancia La Jolla Course

More information